Compare VFF & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | RNA |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 222.5M |
| IPO Year | 2013 | 2025 |
| Metric | VFF | RNA |
|---|---|---|
| Price | $2.10 | $12.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | ★ 646.7K | 127.8K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $215,937,000.00 | N/A |
| Revenue This Year | $12.19 | $88.12 |
| Revenue Next Year | $15.82 | $18.11 |
| P/E Ratio | $102.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $11.13 |
| 52 Week High | $4.99 | $73.06 |
| Indicator | VFF | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 51.20 |
| Support Level | $1.90 | $11.95 |
| Resistance Level | $2.11 | $14.05 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 74.42 | 80.33 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.